Resource impact statement

No significant resource impact is anticipated

We do not expect this guidance to have a significant impact on resources; that is, it will be less than £5 million per year in England (or £9,100 per 100,000 population). This is because medullary thyroid cancer is rare. It is estimated that around 50 people have unresectable, locally advanced or metastatic disease and may be eligible for treatment with cabozantinib.

The technology was previously funded from the Cancer Drugs Fund, but this will stop from 90 days after the publication of the guidance on 28 March 2018. Currently around 6 people receive cabozantinib each year through the Cancer Drugs Fund. This is not anticipated to change after the guidance is published and cabozantinib is available through routine commissioning.  

The list price of cabozantinib has a discount that is commercial in confidence. For enquiries about the patient access scheme contact medical.information.uk@ipsen.com

Cabozantinib is commissioned by NHS England. Providers are NHS hospital trusts.


This page was last updated: 28 March 2018